CL2023001440A1 - Nuevos derivados de indazol acetileno - Google Patents
Nuevos derivados de indazol acetilenoInfo
- Publication number
- CL2023001440A1 CL2023001440A1 CL2023001440A CL2023001440A CL2023001440A1 CL 2023001440 A1 CL2023001440 A1 CL 2023001440A1 CL 2023001440 A CL2023001440 A CL 2023001440A CL 2023001440 A CL2023001440 A CL 2023001440A CL 2023001440 A1 CL2023001440 A1 CL 2023001440A1
- Authority
- CL
- Chile
- Prior art keywords
- acetylene derivatives
- new indazole
- indazole
- new
- acetylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20210859 | 2020-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001440A1 true CL2023001440A1 (es) | 2023-12-01 |
Family
ID=73654642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001440A CL2023001440A1 (es) | 2020-12-01 | 2023-05-18 | Nuevos derivados de indazol acetileno |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12686682B2 (enExample) |
| EP (1) | EP4255908A1 (enExample) |
| JP (1) | JP7840327B2 (enExample) |
| KR (1) | KR20230116799A (enExample) |
| CN (1) | CN116490182A (enExample) |
| AR (1) | AR124170A1 (enExample) |
| AU (1) | AU2021393722A1 (enExample) |
| CA (1) | CA3197659A1 (enExample) |
| CL (1) | CL2023001440A1 (enExample) |
| CO (1) | CO2023006912A2 (enExample) |
| CR (1) | CR20230218A (enExample) |
| IL (1) | IL303064A (enExample) |
| MX (1) | MX2023006176A (enExample) |
| PE (1) | PE20240099A1 (enExample) |
| TW (1) | TWI915460B (enExample) |
| WO (1) | WO2022117477A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2961187T3 (es) | 2019-06-21 | 2024-03-08 | Hoffmann La Roche | Inhibidor de EGFR para el tratamiento del cáncer |
| CN116507328A (zh) | 2020-12-01 | 2023-07-28 | 豪夫迈·罗氏有限公司 | 新的吲唑衍生物 |
| EP4522113A1 (en) * | 2022-05-13 | 2025-03-19 | F. Hoffmann-La Roche AG | Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1252693A1 (zh) | 2015-06-30 | 2019-05-31 | Dana Farber Cancer Institute, Inc. | Egfr抑制剂及其使用方法 |
| TW201834651A (zh) | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| WO2018220149A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Compounds |
| ES2927480T3 (es) | 2017-06-02 | 2022-11-07 | Hoffmann La Roche | Compuestos de isoindolina-acetileno para el tratamiento del cáncer |
| IL279800B2 (en) | 2018-06-29 | 2024-02-01 | Hoffmann La Roche | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use |
| ES2961187T3 (es) | 2019-06-21 | 2024-03-08 | Hoffmann La Roche | Inhibidor de EGFR para el tratamiento del cáncer |
| US20220315577A1 (en) | 2019-06-21 | 2022-10-06 | Hoffmann-La Roche Inc. | New egfr inhibitors |
| TW202115073A (zh) | 2019-06-21 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎的egfr抑制劑 |
| AR120799A1 (es) | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr |
| AR120800A1 (es) | 2019-12-20 | 2022-03-16 | Hoffmann La Roche | Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr |
| CN116507328A (zh) | 2020-12-01 | 2023-07-28 | 豪夫迈·罗氏有限公司 | 新的吲唑衍生物 |
| JP7798887B2 (ja) | 2020-12-01 | 2026-01-14 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| JP2025515833A (ja) | 2022-05-13 | 2025-05-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| EP4522113A1 (en) | 2022-05-13 | 2025-03-19 | F. Hoffmann-La Roche AG | Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer |
-
2021
- 2021-11-29 IL IL303064A patent/IL303064A/en unknown
- 2021-11-29 MX MX2023006176A patent/MX2023006176A/es unknown
- 2021-11-29 AR ARP210103288A patent/AR124170A1/es not_active Application Discontinuation
- 2021-11-29 PE PE2023001615A patent/PE20240099A1/es unknown
- 2021-11-29 CN CN202180079840.XA patent/CN116490182A/zh active Pending
- 2021-11-29 KR KR1020237018340A patent/KR20230116799A/ko active Pending
- 2021-11-29 US US18/255,083 patent/US12686682B2/en active Active
- 2021-11-29 JP JP2023527318A patent/JP7840327B2/ja active Active
- 2021-11-29 CA CA3197659A patent/CA3197659A1/en active Pending
- 2021-11-29 WO PCT/EP2021/083279 patent/WO2022117477A1/en not_active Ceased
- 2021-11-29 CR CR20230218A patent/CR20230218A/es unknown
- 2021-11-29 EP EP21816073.7A patent/EP4255908A1/en active Pending
- 2021-11-29 AU AU2021393722A patent/AU2021393722A1/en active Pending
- 2021-11-30 TW TW110144518A patent/TWI915460B/zh active
-
2023
- 2023-05-18 CL CL2023001440A patent/CL2023001440A1/es unknown
- 2023-05-26 CO CONC2023/0006912A patent/CO2023006912A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022117477A1 (en) | 2022-06-09 |
| IL303064A (en) | 2023-07-01 |
| TW202237611A (zh) | 2022-10-01 |
| MX2023006176A (es) | 2023-06-08 |
| KR20230116799A (ko) | 2023-08-04 |
| US20240002390A1 (en) | 2024-01-04 |
| CO2023006912A2 (es) | 2023-06-09 |
| CR20230218A (es) | 2023-07-07 |
| PE20240099A1 (es) | 2024-01-18 |
| AU2021393722A1 (en) | 2023-04-13 |
| CA3197659A1 (en) | 2022-06-09 |
| TWI915460B (zh) | 2026-02-21 |
| EP4255908A1 (en) | 2023-10-11 |
| US12686682B2 (en) | 2026-07-21 |
| JP7840327B2 (ja) | 2026-04-03 |
| JP2023550902A (ja) | 2023-12-06 |
| CN116490182A (zh) | 2023-07-25 |
| AR124170A1 (es) | 2023-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001529A1 (es) | Nuevos derivados de metilquinazolinona | |
| PE20231938A1 (es) | Inhibidores de cdk y metodos de uso de estos | |
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| CO2023006912A2 (es) | Nuevos derivados de indazol acetileno | |
| CO2026002343A2 (es) | Inhibidores de pi3k | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| CL2023003662A1 (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| CU20210016A7 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| CL2022001353A1 (es) | Inhibidores de egfr | |
| CL2024001481A1 (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| CL2021003139A1 (es) | Compuestos tricíclicos | |
| CL2023002908A1 (es) | Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3 | |
| CO2022008313A2 (es) | Compuestos químicos | |
| AR131472A1 (es) | Moduladores de nampt | |
| CO2022012773A2 (es) | Moduladores de nampt | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| UY31854A (es) | Derivados sustituidos de 3-oxo-isoindolin-1- carboxamidas n-sustituidas y aplicaciones | |
| CO2025010725A2 (es) | Compuestos moduladores de receptores de dopamina d3/d2 | |
| MX2022005415A (es) | Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo. | |
| ECSP24038829A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |